TrialBMC musculoskeletal disorders2022

Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial.

Mingcheng Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.